Clinical Study
De Novo Donor-Specific HLA Antibody Development and Peripheral Cells in Kidney Transplant Recipients: A Place for Interaction?
Table 3
Graft function according to DSA development (1st year after KT).
| | All (%) | DSA negative (%) | DSA positive (%) | |
| Graft function at 1 month | | | | | SCr (mg/dL) | | | | 0.096 | eGFR (by MDRD, mL/min) | | | | 0.167 | Graft function at 12 months | | | | | SCr (mg/dL) | | | | 0.481 | eGFR (by MDRD, mL/min) | | | | 0.759 | Deltas (12 months versus 1 month) | | | | | SCr (mg/dL) | | | | 0.053 | eGFR (by MDRD, mL/min) | | | | 0.759 | Graft function in 2010 | | | | | SCr (mg/dL) | | 1.54 ± 1.91 | | 0.181 | eGFR (by MDRD, mL/min) | | 79.45 ± 26.96 | | 0.081 | Deltas (2010 versus 1 month) | | | | | SCr (mg/dL) | | 0.26 ± 1.99 | | 0.129 | eGFR (by MDRD, mL/min) | | 13.14 ± 25.47 | | 0.097 |
|
|